Results 11 to 20 of about 55,676 (335)
Janus Kinases in Leukemia. [PDF]
Cancers (Basel), 2021 Janus kinases (JAKs) transduce signals from dozens of extracellular cytokines and function as critical regulators of cell growth, differentiation, gene expression, and immune responses. Deregulation of JAK/STAT signaling is a central component in several human diseases including various types of leukemia and other malignancies and autoimmune diseases ...
Raivola J +3 more
europepmc +6 more sources
Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation, [PDF]
Anais Brasileiros de Dermatologia, 2020 Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective.
Melpone Komnitski +3 more
doaj +1 more source
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Pharmacological Research, 2022 The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of ...
Robert Roskoski, Jr.
doaj +1 more source
New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
Pharmaceuticals, 2022 Janus kinases (JAK) are a family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) that transduce cytokine-mediated signals through the JAK–STAT metabolic pathway.
Annalisa Marcuzzi +6 more
doaj +1 more source
Janus kinases: dermatological perspective, a review
Journal of the Egyptian Women’s Dermatologic Society, 2020 Janus kinases (JAKs) are a group of nonreceptor intracellular tyrosine kinases that could modify cytokine-mediated signals through the JAK-signal transducer and activator of transcription pathway.
Hanan R Nada +3 more
doaj +1 more source
Pharmaceuticals, 2022 Systemic sclerosis and systemic lupus erythematosus represent two distinct autoimmune diseases belonging to the group of connective tissue disorders.
Przemysław Kotyla +3 more
doaj +1 more source
Basics of Janus kinases: a review
Journal of the Egyptian Women’s Dermatologic Society, 2020 Janus kinases (JAKs) are a group of nonreceptor intracellular tyrosine kinases that could modify cytokine-mediated signals through the JAK-signal transducer and activator of transcription (STAT) pathway. The intracellular signaling pathway JAK/STAT has a
Hanan R Nada +3 more
doaj +1 more source
Molecules, 2022 Human hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of death across the world. Recent evidence suggests that STAT3 regulates proliferative, survival, metastasis, and angiogenesis genes in HCC.
Manal Alfwuaires +2 more
doaj +1 more source
The Janus kinases (Jaks) [PDF]
Genome Biology, 2004 The Janus kinase (Jak) family is one of ten recognized families of non-receptor tyrosine kinases. Mammals have four members of this family, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2). Birds, fish and insects also have Jaks. Each protein has a kinase domain and a catalytically inactive pseudo-kinase domain, and they each bind cytokine receptors ...
Yamaoka, Kunihiro +5 more
openaire +3 more sources
The role of janus kinases in the treatment of autoimmune skin diseases [PDF]
Farmacja Polska, 2021 The JAK / STAT signaling pathway is a pleiotropic signal transduction pathway for many biochemical substances that are ligands, for example cytokines, growth factor, leptin, erythropoietin or interferons.
Arnold Kukowka +3 more
doaj +1 more source